

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (Currently Amended) Sustained release tablet containing 1.5 to 2.5 % of total mass of the tablet of indapamide, 30 to 80 % of total mass of the tablet of lactose monohydrate, 2 to 10 % of total mass of the tablet of copovidone, 20 to 65 % of total mass of the tablet of hypromellose, and 0.1 to 5 % of total mass of the tablet of lubricant.
2. (Previously Presented) The tablet according to claim 1, wherein said lubricant comprises at least one of magnesium stearate and anhydrous colloidal silica.
3. (Previously Presented) The tablet according to claim 1, wherein the hypromellose has a viscosity from 1,000 to 20,000 cP.
4. (Previously Presented) Process of manufacturing sustained release tablet containing indapamide, comprising mixing indapamide with lactose monohydrate and copovidone and then moisturizing the mixture with purified water and performing granulation after which the granulate is dried, cooled, mixed with hypromellose and lubricant and compressed in tableting machine.
5. (Previously Presented) The process according to claim 4, wherein said lubricant comprises at least one of magnesium stearate and anhydrous colloidal silica.
6. (Previously Presented) The process according to claim 4, wherein the hypromellose has a viscosity from 1,000 to 20,000 cP.